Our observations provide strong evidence that TAS-115 can serve as a multiple tyrosine kinase inhibitor which can impede c-MET and PDGFRα signalling and may offer the distinct clinical advantages even when used as a monotherapy for patients with SS tumours driven by either c-MET or PDGFRα pathways. This evidence concerns the gene PDGFRA and neoplasm.